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AbstrAct
the therapeutic window of opportunity in rheumatoid 
arthritis (RA) is often referred to. However, some have 
questioned whether such a period, in which the disease 
is more susceptible to disease-modifying treatment, 
really exists. observational studies are most frequently 
referenced as supporting evidence, but results of such 
studies are subject to confounding. in addition formal 
consensus on the definition of the term has never been 
reached. we first reviewed the literature to establish 
if there is agreement on the concept of the window of 
opportunity in terms of its time period and the outcomes 
influenced. Second, a systemic literature search was 
performed on the evidence of the benefit of early versus 
delayed treatment as provided by randomised clinical 
trials. we observed that the concept of the window of 
opportunity has changed with respect to timing and 
outcome since its first description 25 years ago. there 
is an ‘old definition’ pointing to the first 2 years after 
diagnosis with increased potential for disease-modifying 
treatment to prevent severe radiographic damage and 
disability. Strong evidence supports this concept. A ‘new 
definition’ presumes a therapeutic window in a pre-RA 
phase in which the biologic processes could be halted and 
RA development prevented by very early treatment. this 
definition is not supported by evidence, although is less 
well studied in trials. Some suggestions for future research 
in this area are made.
InTroduCTIon
Outcomes for patients with rheumatoid 
arthritis (RA) have changed dramatically 
over the last 25 years. These advances have 
been attributed to the development and use 
of novel disease-modifying drugs (including 
biologics), treat-to-target strategies resulting 
in better control of disease activity, and the 
earlier initiation of disease-modifying treat-
ments.
The rationale behind earlier treatment initi-
ation is that it allows modulation of biologic 
processes while they are in a less mature 
and more reversible stage.1 2 This stage has 
previously been referred to as a therapeutic 
window of opportunity.1 2 Nevertheless, 
varying definitions exist of the window of 
opportunity. The first mention of a window 
of opportunity in RA was in 1992 by Dawes 
and Symmons.3 At that time it was described 
as ‘a small window of opportunity (2 years) in 
which to get the disease in remission before 
irreversible damage is done to joints’. Since 
then, the term ‘window of opportunity’ has 
been increasingly used in the rheumatolog-
ical literature. However some have ques-
tioned whether such a period, in which the 
disease is more susceptible to disease-mod-
ifying treatment, really exists, and formal 
consensus on the definition of the term has 
never been reached.
In this Viewpoint we set out to propose a defi-
nition of the ‘window of opportunity’ based 
on data obtained from the literature. First we 
questioned whether or not the term ‘window 
of opportunity’ has been used in a consistent 
way since 1992. To address this, we reviewed 
the literature on articles that used the term 
’window of opportunity’ in the context of RA. 
We explored whether there was consensus in 
terms of the long-term outcomes that were 
considered to benefit from early treatment, 
as well as on the time period, expressed as 
the symptom or disease duration, that was 
proposed to cover the window of opportunity. 
Second, we determined the level of evidence 
for the association between the timing of 
intervention and the disease outcomes that 
were identified in the first part. Although a 
previous literature review concluded that 
prolonged symptom duration at treatment 
initiation in patients with classified RA is asso-
ciated with more radiographic progression 
and a lower chance of achieving disease-mod-
ifying antirheumatic drug (DMARD)-free 
sustained remission (findings that may 
support the presence of a window of oppor-
tunity), this conclusion was largely driven by 
findings from observational cohort studies.4 
In such cohort studies, the timing of DMARD 
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start was not determined by randomisation. Therefore, 
a combination of patient and environmental character-
istics, both known and unknown, may have influenced 
when DMARD therapy was initiated. Because of this, the 
causality of the associations with symptom duration is 
susceptible to confounding and reverse causation bias. 
Randomised controlled trials (RCTs) do not have this 
drawback. Therefore we systemically searched the liter-
ature on RCTs evaluating the effect of early (vs delayed, 
thus initial treatment with placebo) treatment with 
DMARDs. We exclusively concentrated the present liter-
ature search on findings from RCTs. We studied RCTs 
performed in patients with classified RA. Moreover, as 
the field of RA has moved towards identifying patients 
in earlier disease phases, in the current search we also 
performed RCTs performed in patients with undiffer-
entiated arthritis (UA) and arthralgia without clinically 
apparent arthritis.
Is there consensus on how to define the window of 
opportunity?
A generic search on PubMed on (‘((rheumatoid arthritis) 
AND window of opportunity)’) resulted in 89 articles; 
evaluation of full texts revealed 75 relevant articles (both 
original articles as well as other types of papers) on the 
window of opportunity.
timing of the window of opportunity
In 37 of 75 (49%) articles, no exact duration of the 
window of opportunity was included in the description; 
these articles often used general terms, like ‘early’. Other 
articles did not include a chronological period, but a 
disease phase, such as the phase preceding radiographic 
damage (two articles)5 6 or preceding RA development 
(five articles).7–11 With regard to studies that mentioned 
a specific time duration, some studies described the 
window to encompass the first 2 years after disease onset 
(nine articles).3 6 10 12–17 As illustrated in figure 1A, these 
articles were mainly written in the 1990s and early 2000s. 
The most frequently used time description period encom-
passed the first 12 weeks or 3 months after symptom onset 
(19 articles)1 4 6 10 12 18–31; the majority of these papers 
were published after 2010 (figure 1A). Hence, as time 
has passed, the window of opportunity has been assumed 
to be confined to a shorter period occurring in an earlier 
phase of the disease.
Long-term outcomes
Twenty-six out of 75 articles (35%) used general terms 
with regard to the long-term outcomes that could be 
achieved when treatment is started within the window 
of opportunity (eg, ‘sustained clinical benefits’ or 
‘better outcomes’). The most frequently mentioned 
specific outcome was prevention or slowing of radi-
ographic damage (40 articles).3–6 10 12–18 22 24 26 30–54 
The second most frequently mentioned outcome was 
remission, either clinical remission, Disease Activity 
Score (DAS) remission or drug-free remission (22 
articles).1 10 15 16 18 19 22 24–26 31 34 46 48 49 55–61 Furthermore, six 
articles mentioned that treatment within the window of 
opportunity could result in cure6 14 29 30 49 62 of RA, and six 
articles even mentioned prevention of RA as the outcome 
of treatment within the window of opportunity.7–11 61 As 
shown in figure 1B, these latter outcomes were present in 
more recent descriptions of the window of opportunity.
In conclusion, the definition of the window of opportu-
nity as was retrieved from the literature revealed that the 
concept has changed over time. Whereas it was previously 
defined as a treatment period in the first 2 years after 
disease onset in which joint damage could be halted (‘old 
definition’), it is increasingly considered to represent a 
period before the diagnosis is established in which treat-
ment could potentially prevent RA development (‘new 
definition’).
EvIdEnCE obTaInEd from randomIsEd ClInICal TrIals In 
favour of Early TrEaTmEnT
Next, in order to determine the level of evidence of the 
associations that are the basis of these definitions, we 
systematically assessed databases (PubMed, Medline, 
Embase) for RCTs that compared early versus delayed 
treatment with DMARDs in different disease phases (RA, 
UA and arthralgia preceding clinical arthritis) (see online 
supplementary methods for used terms). Patients in all 
these phases required to be DMARD-naïve at trial entry. 
Delayed treatment was defined as absence of DMARD use 
for a certain period. Hence an early treatment group was 
compared with a group that only used placebo (please 
see online supplementary methods for the inclusion 
and exclusion criteria that were used). The quality of all 
included studies was determined using a 15-point quality 
list that was adapted from lists previously used in system-
atic reviews4 63 (online supplementary tables 1 and 2). As 
previously,4 studies with a quality score ≥75% were consid-
ered high-quality studies. Due to heterogeneity in study 
designs, pooled effect estimates were not calculated, but 
a best-evidence synthesis was performed, based on the 
method described by the Cochrane Collaboration Back 
Review Group (online supplementary table 3).64
rCTs in early ra
First we searched the literature for RCTs in early RA 
(disease duration <2 years) comparing early DMARD 
initiation with non-DMARD therapy or delayed DMARD 
therapy. A total of 11 trials were identified, all published 
between 1988 and 2003 (table 1); 9 trials assessed the 
outcome radiographic damage17 65–72 and 8 functional 
disability.17 65 69–74
Radiographic damage in RA
All nine RCTs included DMARD-naïve patients with a 
disease duration of <2 years who fulfilled the classifica-
tion criteria for RA (either the 1958 or the 1987 criteria) 
(table 1). Follow-up ranged between 6 months and 5 
years. Different DMARDs (gold, sulfasalazine, hydrox-
ychloroquine, methotrexate [MTX] and prednisone) 
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Figure 1 Results from literature search on the concept of the window of opportunity in rheumatoid arthritis (RA) with regard 
to its time period (A) and long-term outcome that is influenced (B). The bars correspond to the number of times a specific time 
period or long-term outcome was mentioned in the 75 articles mentioning the window of opportunity in RA. As some articles 
mentioned more than one time period or outcome, and other papers did not mention a specific time period or outcome at all, 
the numbers in the bars do not necessarily add up to 75.
and different measures for radiographic damage (Larsen 
score, [modified] Sharp score, presence of erosions and 
erosion area) were used. A significant benefit for the 
early DMARD arm with regard to radiographic damage 
was shown in five RCTs,17 65 68 70 71 of which three were 
of high quality17 65 70 (two of these reported on the same 
trial).17 65 Three RCTs showed a statistically non-signifi-
cant benefit for the early DMARD arm,66 67 69 and in one 
trial there was no effect.72 Since there were consistent 
findings in multiple high-quality RCTs (as well as in 
low-quality RCTs), there is strong evidence to conclude 
that early DMARD initiation results in better radiographic 
outcomes (figure 2). Importantly, earlier treatment 
resulted in lower absolute levels of joint damage and in 
lower progression rates (ie, less steep progression curves 
over time).17 65 70 Especially the latter finding of less rapid 
rise over time is suggestive of true disease modification. 
With respect to timelines, the early treatment group in 
these trials started DMARDs ~6–12 months earlier than 
the delayed group (table 1).
Functional disability
All eight RCTs that measured functional disability as 
outcome (table 1) included DMARD-naïve patients 
fulfilling the classification criteria for RA (1958 or 1987) 
with a disease duration <2 years. Follow-up ranged 
between 36 weeks and 5 years. Different measures of func-
tional disability were used (Health Assessment Question-
naire, Keitel Functional Index, Arthritis Impact Measure-
ment Scales and McMaster-Toronto Arthritis Patient Pref-
erence Disability Questionnaire). Seven of the RCTs were 
of high quality. However, four different study populations 
were described, as three articles were long-term follow-up 
papers of previously reported study populations.17 72 74 
Four out of seven high-quality studies revealed a signifi-
cant benefit for the early DMARD arm,17 65 69 73 of which 
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Early arthritis
Figure 2 Summary of evidence for randomised controlled trials on the effect of early versus delayed treatment with disease-
modifying antirheumatic drugs per disease phase. RA, rheumatoid arthritis; UA, undifferentiated arthritis.
two reported on the same population.17 65 Of the other 
three high-quality studies, two reported a non-significant 
benefit for early treatment.72 74 The early group started 
DMARDs ~6–12 months earlier than the delayed group. 
Because of consistent findings in multiple high-quality 
RCTs, there is strong evidence for early DMARD initiation 
with regard to improved functional outcome (figure 2).
rCTs in ua aiming to prevent ra development
Next the literature was searched for RCTs in patients 
with UA (online supplementary methods). Six articles, 
reporting on five RCTs, compared DMARD treatment 
with placebo treatment in patients with UA (table 2). 
Different definitions of UA and inclusion criteria were 
used (table 2). Follow-up durations ranged between 1 
and 5 years, and different DMARDs were investigated 
(MTX, infliximab, methylprednisolone and abatacept). 
The outcome was RA according to the 1987 criteria for 
RA75–78 or the clinical diagnosis.79 80 Four RCTs were of 
high quality.76 77 79 80 None of the trials reached a signif-
icant difference in the primary outcome, but all four 
high-quality studies showed a tendency towards less RA 
development in the DMARD arm. Interestingly a recent 
meta-analysis of trials in patients with UA or very early RA 
by Hilliquin et al81 did show a significant risk reduction 
on RA development in the case of DMARD initiation in a 
pre-RA phase when all trials were combined in one anal-
ysis.81 Nonetheless there is no conclusive evidence from 
individual RCTs that early treatment in patients with UA 
prevents progression to RA as none of the individual 
trials revealed a significant reduction (figure 2).
A difficult issue here is that the outcome in the trials 
was mostly fulfilment of the 1987 criteria, and that the 
concept of RA, at least with respect to classification, has 
changed in the last decennium.82 Some of the patients 
previously considered as UA may currently be diagnosed 
or classified as RA. On the other hand, patients with UA 
with a low risk of RA were also included. As demonstrated 
recently, such non-informative inclusions diminish the 
power to detect differences83 and may also have contrib-
uted to negative results.
Hopefully, a well-powered, placebo-controlled trial 
will be done in the nearby future to determine conclu-
sively that early DMARD treatment in UA is beneficial in 
preventing progression to RA.
rCTs in arthralgia without clinical arthritis aiming to prevent 
ra development
Finally the literature was searched for RCTs (described 
in full papers) performed in patients considered at 
risk for RA development but without arthritis (online 
supplementary methods). One RCT was identified 
that included seropositive patients with arthralgia who 
were shared epitope-positive (table 3).84 Patients were 
randomised to either dexamethasone or placebo and 
followed for a median of 26 months. After this period, 
there was no difference in arthritis development between 
the two arms. Thus, no evidence from RCTs yet exists for 
prevention of arthritis by initiating DMARD treatment 
in patients with arthralgia without clinical arthritis with 
regard to arthritis/RA development (figure 2). However, 
several randomised clinical trials are currently ongoing 
and results are awaited in the next 5 years.7
dIsCussIon and fuTurE pErspECTIvEs
The term ‘window of opportunity’ is commonly used 
within the field of RA, although its definition has changed 
over the last 25 years. There is an ‘old definition’ indi-
cating that the therapeutic window lies within the first 2 
years after disease onset, and treatment within it results 
in less radiographic damage and disability. We have here 
demonstrated that there is convincing evidence for this 
effect based on data from RCTs, particularly when treat-
ment was delayed for 6–12 months after diagnosis, due 
to the use of placebo medication during this period. 
Notably, earlier treatment resulted in absolute lower 
levels of radiographic joint destruction and in slower 
progression rates. Lower absolute levels were possibly 
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only the consequence of an earlier start, whereas a less 
steep rise in joint destruction is suggestive for true disease 
modification. In addition to an ‘old definition’, a ‘new 
definition’ is used in the literature as well. This states that 
the window could even lie in a phase preceding diagnosis 
or fulfilment of classification criteria for RA and that 
treatment initiated could possibly result in prevention 
of RA. However, this definition is not (yet) supported by 
evidence from RCTs.
Interpreting data from studies addressing the concept 
of a window of opportunity is challenging. One particular 
issue relates to understanding its duration. Measuring 
the duration of the window requires that a starting point 
is clearly defined. Many studies exploring the concept of 
a window of opportunity will simply report ‘disease dura-
tion’ and will conclude that treating patients with a disease 
duration of less than x months is associated with improved 
outcomes compared with treating patients with disease 
duration of greater than x months. However, when that 
x months is timed from is often inadequately described. 
Possibilities include when the patient first developed (1) 
inflammatory-type joint symptoms, (2) patient-reported 
joint swelling, (3) physician-observed joint swelling and 
(4) physician-documented fulfilment of the RA classifica-
tion criteria.85 Clearly adopting different definitions of a 
starting point for the disease onset will lead to different 
durations of the therapeutic window.21 Although some 
recall bias may be present when collecting information 
about starting points, especially when this was a long 
time ago, specifying the different starting points using 
uniform definitions will promote comparability between 
studies and the interpretation of findings.
Another issue relates whether the concept of a window 
of opportunity requires that there must be a time after 
which it closes, that is, a time after which intervention is 
not as effective as it was if used during the window. Trials 
have used placebo regimens for defined periods of time, 
but the rationale for the duration of placebo treatment 
is never discussed. Many observational studies dichoto-
mised symptom duration and compared outcomes; here 
a cut-off was frequently placed at 3 months after symptom 
onset. However this choice actually refers back to two 
observational studies revealing that treatment initiation 
within 3 months after symptom onset was associated 
with less damage and more remission; evidence for the 
choice of this time period was not provided and other 
time periods were not explored.31 86 Thus far only one 
study evaluated the time course and provided suggestive 
evidence that a confined period in which treatment is 
more effective is more likely than a general ‘the earlier 
the better’ effect.19
In the first part of this Viewpoint, we assessed the most 
commonly used definitions of the window of opportunity. 
A limitation is that this was done by a literature search in 
one database. We presume that a search in more data-
bases and also incorporating different terminology may 
have yielded some additional papers providing descrip-
tions of the window of opportunity. However, we expect 
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that a more systematic search will not result in different 
conclusions regarding the long-term disease outcomes 
and time periods most frequently mentioned in the 
different time periods (as presented in figure 1). In 
the second part in contrast, we determined the level of 
evidence. Here a systematic literature search of results 
obtained from RCTs was required. Due to heterogeneity 
in study designs, meta-analyses were not possible, but a 
best-evidence synthesis, based on the method described 
by the Cochrane Collaboration Back Review Group, was 
performed.
The present review of the literature demonstrated 
that different definitions of the window of opportunity 
are used, of which two definitions were common. It is 
clarifying if subsequent studies that use the term the 
window of opportunity will specify which definition is 
meant. The current work does neither allow to make 
a statement about the best definition of the window 
of opportunity, nor determine the optimal period for 
starting disease-modifying antirheumatic treatment. This 
is subject for future studies.
ConClusIon
In summary, while the concept of a window of oppor-
tunity in RA is widely used, different definitions of this 
window exist. We propose to differentiate an ‘old’ and 
a ‘new definition’. The ‘old definition’ points to the 
first 1–2 years after diagnosis with increased potential 
for disease-modifying treatment to prevent severe radi-
ographic damage and disability, whereas the ‘new defini-
tion’ presumes a therapeutic window in a pre-RA phase 
in which the biologic processes could be halted and RA 
development prevented by very early treatment. A review 
of RCTs revealed a high level of evidence for the ‘old 
definition’ but no scientific evidence for the ‘new defi-
nition’. As there were relatively few trials performed in 
pre-RA phases, more research is needed to verify the new 
definition. Furthermore, to arrive at an evidence-based 
new definition of the window of opportunity, including 
information on its duration and possible closing, future 
trials should use adequately described definitions of the 
starting point.
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